Zhi Tong Cai Jing·2026-01-07 06:55Core Viewpoint - DBS has raised the target price for Manulife Financial (00945) from HKD 290 to HKD 310 while maintaining a "Buy" rating, indicating confidence in the stock's potential for continued valuation re-rating [1] Group 1: Financial Performance - Manulife Financial reported better-than-expected performance in Q3 2025, with new business value increasing by 11% year-on-year, and a 7% growth in the Asia region [2] - The growth is attributed to a shift in the product mix towards higher-margin health insurance products, particularly in the Asian and US markets, which has effectively improved profit margins and driven business growth [2] - New business contract service margins saw a significant year-on-year increase of 25%, with Asia's new business contract service margins also recording a 20% year-on-year growth [2] Group 2: Strategic Initiatives - Manulife's innovation strategy focuses on growth, emphasizing strong growth potential in both Asian and global wealth and asset management businesses [1] - The company is expanding its operations in Canada and the US to maintain a diversified and balanced global investment portfolio [1] - A joint venture with Mahindra to enter the Indian insurance market is expected to add growth opportunities, leveraging Mahindra's strong brand and execution track record [2] - The timing of the entry into the Indian market is strategic, given the improving digital infrastructure and favorable regulatory environment for foreign insurance companies [2]